Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AKTX
- Price
- 1.07
- Stock movement down
- -0.04 (-3.60%)
- Company name
- Akari Therapeutics PLC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 22.09M
- Ent value
- 29.27M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -37.14%
- 1 year return
- -17.69%
- 3 year return
- -64.44%
- 5 year return
- -47.95%
- 10 year return
- -50.34%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AKTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 20.65M |
| EPS (TTM) | -1.60 |
| FCF per share (TTM) | -0.86 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -13.00K |
| Operating income (TTM) | -20.16M |
| Net income (TTM) | -19.52M |
| EPS (TTM) | -1.60 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.25M |
| Net receivables | 0.00 |
| Total current assets | 2.73M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 2.73M |
| Accounts payable | 4.78M |
| Short/Current long term debt | 1.00M |
| Total current liabilities | 9.43M |
| Total liabilities | 9.43M |
| Shareholder's equity | -6.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -10.43M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -10.43M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -714.11% |
| Return on Invested Capital | 342.88% |
| Cash Return on Invested Capital | 183.20% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.15 |
| Daily high | 1.15 |
| Daily low | 1.07 |
| Daily Volume | 11K |
| All-time high | 5000.00 |
| 1y analyst estimate | 80.00 |
| Beta | 0.95 |
| EPS (TTM) | -1.60 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AKTX | S&P500 | |
| Current price drop from All-time high | -99.98% | -12.89% |
| Highest price drop | -99.98% | -56.47% |
| Date of highest drop | 28 Feb 2025 | 9 Mar 2009 |
| Avg drop from high | -96.20% | -11.07% |
| Avg time to new high | 2771 days | 12 days |
| Max time to new high | 2770 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
22.09M
Marketcap category
Small-cap
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Clive Stuart Richardson
Country
USA
City
London
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page